In this short video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah, and the Chairman of Board of Directors of Saudi Oncology Society along with Dr. Mark Verrill from Northern Center for Cancer Care at Freeman Hospital, UK discuss the Monarch 2 HR+, HER2- MBC patients’ characteristics and the OS results.
